A clinical trial update for oxytocin was recorded on October 23, 2026. The study, titled "Efficacy of Intravenous Oxytocin to Speed Recovery After THA," is registered under identifier NCT07430228. It is listed as a Phase 2 trial. The trial's current status is enrolling by invitation, meaning participants are being recruited from a preselected group rather than the general public. The trial is designed to examine intravenous oxytocin in the context of recovery following total hip arthroplasty (THA). No results have been posted for this trial as of this update, and no efficacy or safety outcomes have been reported. The information available reflects only the trial's registration status, phase, and enrollment stage. Oxytocin remains an approved compound, and this trial represents one of its ongoing investigational uses. Readers interested in the broader context of oxytocin, including its approved uses and other research activity, can consult the compound overview for additional background.
Oxytocin Phase 2 Trial for Post-THA Recovery Now Enrolling
See the full oxytocin overview
Source: https://clinicaltrials.gov/study/NCT07430228